Drugs and patents in ATC class S01C - ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION

Last updated: August 1, 2026

ATC class S01C covers ophthalmic combinations that pair an anti-inflammatory agent with an anti-infective. The commercial market is mature, fragmented and largely generic. The principal products are corticosteroid-antibiotic combinations such as tobramycin/dexamethasone, neomycin/polymyxin B/dexamethasone and tobramycin/loteprednol. Most first-generation products have lost meaningful compound and formulation exclusivity. Current commercial differentiation depends on preservative-free delivery, suspension performance, dosing convenience, sterile manufacturing, physician familiarity and distribution rather than broad patent protection.

What drugs are included in ATC class S01C?

ATC S01C includes ophthalmic anti-inflammatory and anti-infective combinations. The class is divided primarily by the anti-inflammatory component and the presence of mydriatic agents.

ATC subgroup	Product type	Representative active ingredients
S01CA	Corticosteroids and anti-infectives	Tobramycin/dexamethasone; neomycin/polymyxin B/dexamethasone; tobramycin/loteprednol
S01CB	Corticosteroids, anti-infectives and mydriatics	Corticosteroid-antibiotic combinations with an agent that dilates the pupil
S01CC	Non-steroidal anti-inflammatory agents and anti-infectives	NSAID-antibiotic combinations, generally less commercially prominent in the U.S.

The largest established U.S. products are Tobradex, Maxitrol and Zylet. Tobradex combines tobramycin with dexamethasone. Maxitrol combines neomycin, polymyxin B and dexamethasone. Zylet combines tobramycin with loteprednol etabonate. Their labeled uses generally include steroid-responsive ocular inflammation when bacterial infection exists or is judged likely, subject to product-specific labeling restrictions.[1-3]

Which drugs compete in the S01C ophthalmic market?

Competition is divided between branded fixed-dose combinations, generic equivalents and separate-component prescribing.

Product	Active ingredients	Dosage forms	Original U.S. sponsor or current brand owner	Market position
Tobradex	Tobramycin/dexamethasone	Suspension and ointment	Alcon legacy product; brand ownership and commercialization have changed over time	Established reference product with broad generic competition
Maxitrol	Neomycin/polymyxin B/dexamethasone	Suspension and ointment	Alcon legacy product	Older triple-combination product with generic competition
Zylet	Tobramycin/loteprednol etabonate	Suspension	Bausch + Lomb	Differentiated by the loteprednol steroid and branded positioning
Generic equivalents	Vary by reference product	Suspensions and ointments	Multiple ANDA sponsors	Main volume and price pressure
Non-combination alternatives	Antibiotic, corticosteroid or NSAID products prescribed separately	Drops and ointments	Multiple manufacturers	Substitute for fixed-dose combinations

The clinical and commercial value proposition differs by product. Dexamethasone has strong anti-inflammatory activity but carries familiar steroid-related risks, including intraocular pressure elevation, delayed wound healing and infection-related complications. Loteprednol etabonate is positioned as a corticosteroid with a potentially more favorable intraocular-pressure profile in appropriate patients, although the product remains subject to steroid class warnings and monitoring requirements.[1-3]

What patents protect Tobradex, Maxitrol and Zylet?

The core active-ingredient combinations in the leading S01C products are generally old. Patent protection has therefore shifted from composition claims to formulation, particle-size control, suspension stability, preservative systems, delivery devices and manufacturing processes.

Tobradex patent position

Tobradex contains tobramycin and dexamethasone. Both active ingredients have long histories of ophthalmic use, and generic versions of the combination have been approved in the United States. The primary commercial barrier is therefore not an unexpired composition patent but the ability to meet the reference listed drug's quality, bioequivalence and sterile manufacturing requirements.

Potentially relevant protection historically included patents directed to ophthalmic suspensions, particle distribution, viscosity, sedimentation control and preservative systems. These rights are distinct from the drug's original active-ingredient protection and may apply only to a particular formulation or dosage form.

Maxitrol patent position

Maxitrol contains neomycin, polymyxin B and dexamethasone. Its active ingredients and basic combination are established products. The patent estate is correspondingly mature, with generic competition in both suspension and ointment presentations.

The principal competitive issues are formulation quality, container closure integrity, sterile manufacturing and substitution at the pharmacy level. These issues can affect approval and supply reliability but do not usually create durable market exclusivity comparable to a new chemical entity patent.

Zylet patent position

Zylet combines tobramycin with loteprednol etabonate. Loteprednol etabonate is a newer corticosteroid than dexamethasone and historically supported a stronger product-level patent position than older steroid-antibiotic combinations. The commercial estate has included patents and regulatory exclusivity associated with loteprednol formulations, ophthalmic suspensions and combination products.

The relevant patent analysis must separate:

Loteprednol etabonate composition patents.
Tobramycin-loteprednol combination patents.
Ophthalmic suspension and particle-size claims.
Method-of-use claims for post-operative or inflammatory eye conditions.
Patents listed in the FDA Orange Book against the specific Zylet NDA.

An expired or delisted patent covering the active ingredient does not eliminate the possibility of a later-expiring formulation patent. Conversely, a formulation patent may be narrow and avoidable if an ANDA applicant uses a materially different excipient system or manufacturing process.

When do S01C products lose exclusivity?

Most major S01C products have already lost core market exclusivity. The timing is product-specific because several forms of protection can overlap.

Exclusivity category	Relevance to S01C combinations
New chemical entity exclusivity	Generally unavailable for old antibiotic and corticosteroid ingredients
New clinical investigation exclusivity	May apply to certain new indications, formulations or dosing regimens
Orphan-drug exclusivity	Usually not relevant to these broad ophthalmic indications
Patent exclusivity	Historically important for newer corticosteroid components and specialized formulations
Pediatric exclusivity	May add six months when awarded and linked to qualifying patents or exclusivity
Regulatory exclusivity for a new combination	Depends on the statutory basis and whether the combination qualifies for protection

The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity associated with approved U.S. drug products.[4] Because Orange Book listings can be delisted, expire, or change through patent certifications and litigation, a current freedom-to-operate assessment requires a product-specific review rather than reliance on historical patent summaries.

What is the Orange Book status of S01C drugs?

The Orange Book lists approved drug products, therapeutic equivalence evaluations and, where applicable, patents and exclusivity dates. S01C products can appear in the Orange Book as reference listed drugs with multiple approved generic equivalents.

Key Orange Book questions include:

Whether the reference product has active listed patents.
Whether those patents cover the suspension, ointment, indication or method of use.
Whether an ANDA applicant must submit a Paragraph III, IV or other certification.
Whether a patent is listed against the exact dosage form and strength.
Whether the product has a 180-day first-applicant generic exclusivity period.
Whether the listed patent has expired or been removed.

For older Tobradex and Maxitrol products, the commercial effect of Orange Book patents is generally limited because multiple generic products have reached the market. For Zylet and other products with newer or more complex formulations, Orange Book-listed formulation patents can have greater strategic importance.

How many patents cover S01C ophthalmic combinations?

There is no single patent count for ATC S01C. The class contains multiple active ingredients, dosage forms, sponsors and jurisdictions. A meaningful count must be made at the product level.

A practical patent landscape divides rights into five families:

Patent family	Typical claim scope	Commercial significance
Active ingredient	Chemical compound or salt	High for newer steroids; low for older antibiotics
Fixed-dose combination	Specific antibiotic-steroid pairing	Usually limited for old combinations
Formulation	Suspension, viscosity, particle size, preservative or excipient system	Moderate to high for differentiated products
Method of use	Post-operative inflammation, uveitis or infection-associated inflammation	Depends on label and enforceability
Manufacturing and device	Sterile processing, filling, container or delivery system	Can create operational barriers but rarely blocks all substitutes

The most defensible patent strategy in this class usually relies on several narrow formulation or process patents rather than one broad composition patent.

What formulation patents protect ophthalmic anti-inflammatory and anti-infective products?

Formulation patents are central because ophthalmic suspensions are technically difficult to reproduce. Common claim areas include:

Uniform dispersion of poorly soluble corticosteroid particles.
Particle-size distributions that improve ocular exposure or reduce irritation.
Suspension stability during storage and shaking.
Viscosity control and redispersibility.
Preservative concentration and antimicrobial effectiveness.
Low-dose or preservative-free presentations.
Reduced foaming and improved drop-count consistency.
Container closure systems and multidose dispensers.
Sterile manufacturing and aseptic filling.

A generic applicant may avoid infringement by changing excipients, particle size, preservative selection or manufacturing parameters. The applicant must still demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. A formulation patent can therefore increase development cost without guaranteeing long-term market protection.

Preservative-free technology has particular commercial value in chronic or repeated-use ophthalmic therapy. However, preservative-free delivery can require specialized containers, single-dose packaging or multidose systems that add manufacturing and supply-chain complexity.

Are method-of-use patents important for S01C products?

Method-of-use patents can cover treatment of inflammation after cataract surgery, corneal procedures, anterior uveitis or other steroid-responsive conditions in which bacterial infection is present or suspected.

Their value depends on four factors:

Whether the patented use is included in the reference product label.
Whether the patent is listed in the Orange Book.
Whether the generic applicant can use a section viii statement to omit the patented indication.
Whether physicians and pharmacists will substitute the generic for non-patented uses.

A narrow method-of-use patent is less effective when the product has multiple approved indications and the generic label can omit the protected use. Formulation patents generally present a more direct barrier because they can apply to the product itself rather than a particular indication.

Which companies are challenging S01C products?

Generic ophthalmic manufacturers have challenged or entered against mature S01C reference products through ANDA filings. The market includes large generic companies and specialized ophthalmic manufacturers. Relevant participants have included:

Bausch + Lomb.
Alcon and legacy Novartis ophthalmic businesses.
Akorn and successor or asset purchasers.
Sandoz.
Teva Pharmaceutical Industries.
Apotex.
Dr. Reddy's Laboratories.
Rising Pharmaceuticals.
Amneal Pharmaceuticals.
Micro Labs.
Lupin.
Other regional ANDA sponsors.

The competitive threat is usually a series of ANDA approvals rather than one identifiable challenger. Generic entry can occur through multiple dosage forms, including ophthalmic suspension and ointment, with each presentation requiring separate regulatory and patent analysis.

What Paragraph IV challenges affect S01C products?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed ANDA product. A certification can trigger litigation under the Hatch-Waxman Act and may create a 30-month stay of FDA approval, subject to statutory exceptions and litigation outcomes.[5]

For mature combinations such as Tobradex and Maxitrol, the commercial impact of Paragraph IV activity is usually lower because generic products may already be approved or because the relevant listed patents have expired. For newer or reformulated products, a Paragraph IV challenge can determine whether the reference sponsor retains a period of protected pricing.

The key diligence points are:

The ANDA filing date.
The applicant's certification for each listed patent.
The date of notice to the patent holder.
Whether litigation was filed within 45 days.
The scope of the asserted claims.
The expected 30-month-stay endpoint.
Whether a settlement permits an agreed generic launch date.

What patent litigation and settlements affect this market?

S01C litigation has historically centered on formulation and combination patents rather than the old antibiotic or corticosteroid molecules. Cases may involve:

Infringement of suspension or particle-size claims.
Validity challenges based on obviousness and written description.
Patent listing disputes.
ANDA label carve-outs.
Injunction requests before commercial launch.
Licensing or authorized-generic arrangements.

Settlement terms can include an agreed entry date, a license to launch before patent expiration, supply arrangements, or an authorized generic. The economic effect depends on whether the settlement preserves exclusivity for the branded product and how many other generic applicants remain in the market.

No biosimilar litigation pathway applies to these products. S01C products are small-molecule ophthalmic drugs approved through the NDA/ANDA system, not biologics subject to the Biologics Price Competition and Innovation Act.[6]

What FDA regulatory issues create entry barriers?

FDA approval of an ophthalmic generic requires more than matching the active ingredients. Applicants must address:

Pharmaceutical equivalence.
Sterility.
Preservative effectiveness where applicable.
Container closure integrity.
Suspension uniformity and redispersibility.
Drop size and delivered volume.
Viscosity and pH.
Impurities and degradation products.
Microbial limits and aseptic processing.
Bioequivalence under the applicable ophthalmic guidance.

Suspensions are more difficult to develop than simple aqueous solutions. Differences in particle size, settling behavior and drop delivery can produce regulatory deficiencies even when the active ingredients are identical.

FDA manufacturing findings can also affect supply. Sterile ophthalmic facilities face contamination, particulate and aseptic-processing risks. A manufacturing disruption can temporarily shift market share among approved suppliers without changing the underlying patent position.

How strong is the patent estate for S01C combinations?

The estate is strongest where the product has a newer steroid, a technically differentiated suspension or a proprietary delivery system. It is weakest for old antibiotic-steroid combinations with multiple generic suppliers.

Product profile	Patent strength	Generic entry risk
Old antibiotic-steroid suspension	Low	High
Old antibiotic-steroid ointment	Low	High
Combination containing a newer corticosteroid	Moderate	Moderate
Preservative-free formulation	Moderate	Moderate to high, depending on device and claims
Proprietary multidose delivery system	Moderate to high	Higher development cost, but substitute products remain possible
Product with only method-of-use protection	Low to moderate	High if label carve-out is feasible

Patent strength should be assessed claim by claim. A large number of patents does not necessarily create a strong barrier if the claims are narrow, expired, vulnerable to obviousness attacks or avoidable through a different formulation.

What generic launch scenarios exist for S01C products?

The main launch scenarios are:

Routine generic entry after patent expiry. Multiple ANDA products launch soon after approval, producing rapid price erosion.
First-filer entry after Paragraph IV litigation. One applicant may receive 180-day exclusivity, delaying broader generic competition.
Label-carve-out entry. A generic omits a patented indication and launches without infringing the method-of-use claims.
Formulation-around entry. An applicant changes excipients or particle-size parameters while maintaining pharmaceutical equivalence.
Authorized-generic entry. The brand sponsor licenses or supplies a generic version to manage price competition.
Shortage-driven entry expansion. Supply disruption at one manufacturer allows other approved suppliers to gain temporary share.

The most probable outcome for older S01C products is multi-source generic competition. Branded products can retain share through physician familiarity, payer contracting, packaging, preservative-free options and perceived tolerability.

What is the geographic coverage of S01C patent protection?

Patent protection is territorial. U.S. Orange Book status does not establish protection in Europe, Japan, Canada, China or other markets.

The international landscape differs because:

Patent term calculations vary by jurisdiction.
Supplementary protection certificates may apply in Europe to eligible products.
Patent linkage differs by country.
Generic approval pathways are not uniform.
Some countries rely on national formularies or tender procurement.
Reference products and brand names differ across markets.
Older ophthalmic combinations may be sold under regional brands or hospital channels.

The broad global trend is similar: old combinations face generic pressure, while differentiated formulations and delivery systems have the most defensible remaining protection.

How does S01C compare with standalone ophthalmic anti-inflammatory drugs?

Fixed-dose combinations offer convenience and reduce the number of drops a patient must administer. They also expose patients to an antibiotic even when the infection risk is low or resolved. Standalone corticosteroids, NSAIDs and antibiotics allow more precise treatment selection and dose adjustment.

Issue	Fixed-dose S01C combination	Standalone ophthalmic product
Dosing convenience	Generally better	Requires multiple products when both therapies are needed
Patent protection	Usually mature for older combinations	Can be stronger for newer molecules or delivery systems
Generic substitution	Broad for older products	Broad but product-specific
Formulation complexity	Often high because of suspension stability	Varies by active ingredient
Clinical flexibility	Lower	Higher
Commercial differentiation	Preservative-free delivery, suspension quality and convenience	Molecule, indication, dosing and delivery system

What revenue exposure does S01C patent expiry create?

Patent expiry affects revenue through price erosion, formulary substitution and loss of branded prescription volume. The exposure is greatest when:

The product has high unit sales and limited clinical differentiation.
Several ANDA products launch at the same time.
Payers treat the generic as automatically substitutable.
The product has no meaningful preservative-free or device advantage.
The brand depends on a single formulation.

Revenue retention is more plausible when the sponsor has a portfolio of related ophthalmic products, strong surgeon relationships, differentiated packaging, or supply advantages. The presence of a formulation patent can delay competition, but it does not eliminate substitution from a therapeutically similar product outside the patent scope.

Key Takeaways

S01C is a mature ophthalmic market centered on corticosteroid-antibiotic combinations.
Tobradex, Maxitrol and Zylet are the principal reference products in the U.S. competitive landscape.
Core active-ingredient protection is largely exhausted for older combinations.
Remaining patent value is concentrated in suspensions, particle size, excipients, preservative-free systems, devices and manufacturing processes.
Orange Book analysis must be performed by NDA, dosage form and patent.
Paragraph IV challenges are most commercially important for newer formulations and products containing newer corticosteroids.
No biosimilar pathway applies; competition proceeds through ANDAs and Hatch-Waxman litigation.
Generic entry risk is high for older products and moderate for differentiated formulations.
Sterile manufacturing, suspension quality and container systems are important regulatory and operational barriers.
International patent and regulatory positions cannot be inferred from U.S. Orange Book status.

FAQs About S01C Ophthalmic Combinations

Which S01C product has the strongest patent position?

Products containing newer corticosteroids or proprietary preservative-free delivery systems generally have stronger patent positions than old dexamethasone-antibiotic combinations. The strength depends on active, unexpired claims rather than the number of patents listed.

Can a generic omit an indication protected by a method-of-use patent?

Yes. An ANDA applicant may use a section viii statement to omit a patented indication when the remaining label supports approval and the omission is legally and regulatorily acceptable.

Are Tobradex and Maxitrol still protected by composition patents?

Their old antibiotic-corticosteroid combinations are generally mature and subject to generic competition. Any remaining protection is more likely to involve a particular formulation, dosage form, method of use or delivery system.

Do preservative-free ophthalmic combinations receive separate exclusivity?

A preservative-free presentation may receive patent protection or, in limited circumstances, regulatory exclusivity if it satisfies statutory requirements. The presentation does not automatically receive exclusivity merely because it is preservative-free.

What is the main manufacturing barrier for generic S01C products?

The principal barrier is reproducible sterile manufacture of a stable ophthalmic suspension with comparable particle-size distribution, redispersibility, delivered dose and container performance.

References

U.S. Food and Drug Administration. (2023). Tobradex ophthalmic suspension and ointment prescribing information.
U.S. Food and Drug Administration. (2023). Maxitrol ophthalmic suspension and ointment prescribing information.
U.S. Food and Drug Administration. (2023). Zylet ophthalmic suspension prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: S01C Anti-inflammatory agents and anti-infectives in combination.

Drugs in ATC Class S01C

Subclasses in ATC: S01C - ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION

S01C Ophthalmic Anti-Inflammatory and Anti-Infective Combinations: Market Dynamics and Patent Landscape